Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Assessment and Global Drug Forecast in H2 2016

No of Pages - 70
Publishing Date - October, 2016

Browse detailed TOC, Tables, Figures, and Charts in Global Serial Device Server Consumption 2016 Market Research Report at:
http://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface-antigen-cd40-or-bp50-or-cdw40-or-cd40l-receptor-or-tnfrsf5-or-cd40-pipeline-review-h2-2016-report.html

Latest market pipeline analysis on the Tumor Necrosis Factor Receptor Superfamily has been released by Global Markets Direct. It has been added to the online database of Market Research Hub (MRH). The report is built using data sourced from exclusive databases, SEC filings, clinical trial registries, conferences, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Tumor Necrosis Factor Receptor Superfamily Member 5 Report explained that the expression of CD40 is diverse. CD40 is expressed on a wide range of tumor cells including hodgkin’s and non-hodgkin’s lymphomas, myeloma and some carcinomas including nasopharynx, bladder, kidney and ovary. As observed by the study, tumor necrosis factor promotes an inflammatory response to remove damaging stimuli which include damaged cells, irritants, or pathogens and then begins the therapeutic process.
# Table of Contents

Table of Contents  
Table of Contents 2  
List of Tables 5  
List of Figures 6  
Introduction 7  
Global Markets Direct Report Coverage 7  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) Overview 8  
Therapeutics Development 9  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Stage of Development 9  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Therapy Area 10  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Indication 11  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Products Glance 13  
Late Stage Products 13  
Early Stage Products 14  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Companies 15  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Universities/Institutes 18  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment 20  
Assessment by Monotherapy/Combination Products 20  
Assessment by Mechanism of Action 21  
Assessment by Route of Administration 23  
Assessment by Molecule Type 25  
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development 27  

---  

AbbVie Inc 27  
Apexigen, Inc. 28  
Apopgenix GmbH 29  
Boehringer Ingelheim GmbH 30  
Bristol-Myers Squibb Company 31  
Cellldex Therapeutics, Inc. 32  
F. Hoffmann-La Roche Ltd. 33  
ImmuNext, Inc. 34  
Johnson & Johnson 35

---
Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54

Monoclonal Antibodies to Agonize CD40 for Lymphoma - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55

Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56

RG-7876 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57

SEA-CD40 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Projects 60
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 62
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Featured News & Press Releases 63

Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 63

Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 63
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody 64
Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 64
Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 65
Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno- oncology Therapeutic Antibody APX005M 66
May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform
Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial
Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial
Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors
Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply

Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

Report Details -
Date of Publishing - October, 2016
No of Pages - 70
Single User License - $3500
Multiple User License - $7000

About Market Research HUB: Market Research HUB is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Contact—
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : mailto:sales@marketresearchhub.com
Website : http://www.marketresearchhub.com/